Shinpoong enters into exclusive agreement with HRA Pharma over Ulipristal, uterine fibroids drug

Published: 2010-12-06 06:57:00

Updated: 2010-12-06 06:57:00

Shinpoong Pharmaceutical said on December 2 that it has signed an exclusive licensing agreement with France based HRA Pharma to develop and commercialize ulipristal acetate in Korea for benign gynecological disorders, with a lead indication for the treatment of symptomatic uterine fibroids.

Ulipristal acetate is a selective progesterone receptor modulator (SPRM) that reversibly blocks the pr...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.